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Abstract: The group of pattern recognition receptors includes families of Toll-like receptors, 
NOD-like receptors, C-type lectin receptors, and RIG-I-like receptors. They are key sensors 
for a number of infectious agents, some of which are carcinogenic, and they launch an immune 
response against them. Inherited structural variation in genes encoding these receptors and 
  proteins of their signaling pathways may affect their function, modulating cancer risk and features 
of cancer progression. Relevant malignancies, valuable gene polymorphisms, prime questions 
about future directions, and answers to these questions are analyzed in this review. It is possible 
to suggest that polymorphisms of genes encoding pattern recognition receptors and proteins of 
their signaling pathways may be associated with almost all cancer types, particularly with those 
in which carcinogenic infectious agents are responsible for the substantial share of cases (namely 
gastric cancer, colorectal cancer, liver cancer, cervical cancer, and nasopharyngeal carcinoma). 
The concept of selection of polymorphisms for further oncogenomic investigation, based on a 
combination of results from basic and epidemiological studies, is proposed.
Keywords: pattern recognition receptors, Toll-like receptors, NOD-like receptors, C-type lectin 
receptors, cancer, gene polymorphisms
Introduction
What are pattern recognition receptors?
The group of pattern recognition receptors (PRRs) includes families of Toll-like 
receptors (TLRs), NOD-like receptors, C-type lectin receptors (CLRs), and RIG-I-like 
receptors (RLRs). A summary of the most modern conceptual data about members of 
these families and their structure and functions can be obtained from recent compre-
hensive papers of Kawai and Akira,1 Elinav et al,2 Osorio and Reis e Sousa,3 and Loo 
and Gale.4 Receptors constituting these families are united by two general features. 
Firstly, they directly recognize common antigen determinants of virtually all classes 
of pathogens (so-called pathogen-associated molecular patterns) and initiate immune 
response against them via specific intracellular signaling pathways.1–4 Secondly, they 
recognize endogenous ligands (since they are usually released during cell stress, they 
are called damage-associated molecular patterns), and, consequently, PRR-mediated 
immune response can be activated without the influence of infectious agents.1–4 
Therefore, PRRs may also initiate development of aseptic inflammation caused by 
physical factors such as mechanical pressure, thermal damage, ionizing and nonion-
izing radiation, or chemical factors (eg, acidic damage, alkaline damage, exposure to 
chemical war gases, croton oil or turpentine, exposure to allergens, liberation of toxic   
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substances during tumor disintegration, aseptic necrosis, 
internal bleeding, hemolysis, and autoimmune processes).1–4 
It may promote further progression of inflammation or, on 
the contrary, prevent hazardous infectious complications (the 
combination of these two effects may also be true).1–4 The 
final outcome of PRR working is enhanced production of 
many proinflammatory cytokines participating in plenty of 
the immune system’s processes.1–4 Expression of PRRs on 
different levels (transcriptomic or proteomic) was detected 
in a lot of cells and organs,1–5 providing evidence that these 
receptors control many elements of the complex machinery 
of the human immune system: they allow epithelium and 
endothelium to defend against infectious agents on their own, 
they mediate the activation of adaptive immune response by 
antigen-presenting cells and T-helpers, they stimulate expres-
sion of cell adhesion molecules for leukocyte rolling and for 
other processes of inflammation development, and, finally, 
they contribute to phagocytosis efficacy.5 As a consequence 
of all mentioned above, PRRs play a key role in the realiza-
tion of innate and adaptive immune response. In addition, 
many PRRs have a number of other vital functions apart from 
participation in immune response realization: they may regu-
late various aspects of cell proliferation, survival, apoptosis, 
autophagy, reactive oxygen species generation, pyroptosis, 
angiogenesis, and, consequently, of tissue   remodeling and 
repair.6–9
The fundamental characteristics and diversity of PRR 
functions have led to amazingly rapid research in this 
field, and such investigations are very promising for medi-
cine as the immune system plays a key role in the vast 
majority, if not all, human diseases, and the process of 
discovering new aspects of immune system functioning is 
rapidly ongoing. There is a plethora of papers analyzing 
the significance of PRRs in various diseases. One of the 
most actively explored fields in PRR biology is their role 
in cancer   etiopathogenesis. Not surprisingly, it is (as well 
as tumor immunology in   general) a “hot spot” in cancer 
biology as well.
The role of pattern recognition  
receptors in cancer development
Since PRRs mediate the immune response induced by 
many immunoadjuvants,10,11 and many of them regulate the 
immune response against potentially carcinogenic   infectious 
agents12,13 (Helicobacter pylori,14–17 Epstein–Barr virus 
(EBV),18,19 human papillomavirus,18,19 human herpesvirus-8/
Kaposi sarcoma-associated herpesvirus,18,19 Mycobacterium 
tuberculosis,15–17,20 Streptococcus pneumoniae,15–17,21 entero-
pathogenic Escherichia coli,15–17,22 Shigella flexneri,15–17,23 
Salmonella typhimurium,15–17,24   Borrelia burgdorferi,15–17,25 
  Chlamydophila pneumoniae,15–17 Chlamydia trachomatis,15–17,26 
Chlamydophila psittaci,15–17 and Campylobacter jejuni15–17,27), 
it seems to be possible to stimulate antitumor immunity 
through their enhanced activation.28,29 This hypothesis, origi-
nally developed for TLRs, should be also true for all PRRs 
as well.28,29   According to this suggestion, reinforced PRR 
activation may protect from infectious agents and prevent, 
inhibit, or block carcinogenesis whilst disrupted functioning 
of these PRRs may allow infectious agents or tumor cells to 
avoid recognition by the immune system and, consequently, 
not be eliminated.28,29 At the same time, such PRR activation 
may promote carcinogenesis, creating a proinflammatory 
microenvironment (via action of respective cytokines) that 
is favorable for tumor progression and chemoresistance 
development.30 It may also result in immunosuppression 
caused by chronic   inflammation.28 Chronic inflammation may 
promote the development of cervical, endometrial, ovarian, 
breast, prostate, testicular, nasopharyngeal, lung, esophageal, 
gastric, colorectal, liver, pancreatic,   gallbladder, kidney, 
bladder, lymphatic malignancies, and feasibly several other 
cancer types.11,31 In this case, on the contrary, lower PRR 
activity should minimize effects of chronic inflammation 
such as enhancement of cancer initiation and promotion/
progression and, consequently, decrease probability of tumor 
development.30 So, the situation resembles a double-edged 
sword. The ideal variant, possibly, is the “golden mean” – the 
balance between low and high PRR activity. This hypothesis, 
initially developed for PRRs,29 may also be successfully 
projected on PRR intracellular signaling pathways; if their 
elements are overexpressed/constantly activated, it may lead 
to similar consequences as enhanced PRR activation. On the 
other hand, if members of PRR pathways are   underexpressed/
inactivated/unable to do their work, it may result in the same 
effects that arise after decreased PRR activity, and the ana-
logical “golden mean” in functioning of all genes encoding 
proteins constituting PRR signaling pathways will be the 
optimal variant.
Structural genomic variation
The completion of the Human Genome Project and widespread 
distribution of genotyping technologies have led to an enor-
mous number of studies devoted to the association of inherited 
gene polymorphisms with various diseases. Single nucleotide 
polymorphisms (SNPs) may result in amino acid substitutions 
altering protein function or splicing, and they can also change 
the structure of enhancer sequences   during splicing32 or affect 
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messenger ribonucleic acid (RNA)   stability.33 SNPs may alter 
transcription factor binding motifs, changing the efficacy of 
enhancer or repressor elements,34 and can alter the structure 
of translation initiation codons that may lead to downregula-
tion of wild-type transcript.35 Gene polymorphisms located 
in leucine-rich repeats constituting ectodomain of PRRs 
may affect the ability of the receptor to bind pathogens they 
normally recognize,36 SNPs in transmembrane domain can 
lead to defects of intracellular receptor transport that do not 
allow location of a receptor on the membrane,37 and, finally, 
polymorphisms in the internal domain may result in altered 
interaction with adaptor proteins or in disrupted dimerization. 
So, inherited SNPs of genes encoding PRRs may alter PRR 
expression and activity, modulating cancer risk and, possibly, 
influencing various features of cancer progression. The same 
statement should be true for genes encoding proteins of PRR 
signaling pathways.
Based on the plethora of fundamental and epidemiological 
studies carried out, it is possible to specify two fundamental 
mechanisms for modulation of cancer risk by polymorphisms 
of genes encoding PRRs and proteins of PRR pathways. The 
first mechanism is impairment of the immune response to 
certain pathogens (it can be bacteria, viruses, fungi,   protozoan, 
and helminths), which increases the risk of potentially carci-
nogenic infection and promotes its development along with 
further chronical persistence. The second mechanism is an 
increase in production of proinflammatory cytokines after 
binding of the ligand (exogenous or endogenous), which cre-
ates a condition of carcinogenic chronic inflammation.
Relevant malignancies: the first 
dimension of investigation
There is a variety of cancer types definitely or possibly having 
infectious etiology12,13 that can be associated with inherited 
alterations in genes encoding PRRs and proteins of PRR 
signaling pathways:
•	 esophageal cancer (variation in immune response to 
pathogens infecting esophagus)38
•	 gastric cancer (on the basis of modulation of immune 
response to H. pylori)39,40
•	 cancer of the small bowel (modulation of immune 
response to C. jejuni)41
•	 colorectal cancer (alteration of immune response to many, 
mostly undefined, infectious agents inhabiting the colon 
and rectum)42–44
•	 liver cancer (variation in immune response to hepatitis B 
virus, hepatitis C virus, Helicobacter hepaticus, or liver 
flukes)45,46
•	 gallbladder cancer (modulation of immune response to 
infectious agents found in bile)47
•	 pancreatic cancer (alteration of immune response to 
pathogens inhabiting the pancreas)48
•	 endometrial cancer (modification of immune response 
to several kinds of infectious agents colonizing the 
endometrium)49
•	 cervical cancer (alteration of immune response to human 
papillomavirus and some infectious agents colonizing the 
cervix)50
•	 ovarian cancer (variation in immune response to 
C. trachomatis)51,52
•	 breast cancer (modulation of immune response to some 
viruses infecting the breast)52,53
•	 prostate cancer (variation in immune response to 
  Propionibacterium acnes and other uncertain pathogens 
found in prostate tissue)54
•	 testicular cancer (modification of immune response 
to EBV)55
•	 kidney cancer (variation in immune response to bacteria 
and viruses infecting the kidneys)56
•	 bladder cancer (modulation of immune response to certain 
viruses or Schistosoma spp.)57
•	 nasopharyngeal carcinoma (alteration of immune 
response to EBV)58
•	 lung cancer (variation in immune response to M. tuberculosis, 
S. pneumoniae, C. pneumoniae, and, possibly, to other 
infectious agents causing chronic inflammatory lung 
diseases)52,59
•	 lymphoma (modification of immune response to EBV 
and many other infectious agents such as B. burgdorferi 
or H. pylori)60,61
•	 Kaposi sarcoma (variation in immune response to human 
herpesvirus-8/Kaposi sarcoma-associated herpesvirus 
infection).62
Selection of valuable 
polymorphisms: the second 
dimension of investigation
It is important to remember that there are two main compo-
nents determining the importance of the SNP in programs 
of cancer prevention based on genomic risk markers: the 
odds ratio value between cases and controls (as in the whole 
population and subgroups) and the prevalence of the poly-
morphism in the population, and they both may vary in 
different geographic regions. It is desirable to develop not 
one general program, but a number of individual programs 
for different countries/populations. At the moment, it is 
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possible only to recommend a list of polymorphisms for 
further investigation since only a small number of studies 
with perfect design were carried out. The list of relevant 
polymorphisms that can be admitted as the most promis-
ing for further oncogenomic investigations may be created 
according to the following rules.
A gene polymorphism may be included into the short list 
for further oncogenomic studies if:
•	 The SNP leads to substantial functional consequences 
on the molecular level (for instance, it strongly affects 
transcription, splicing, translation, stability and transport 
of pre-messenger RNA, messenger RNA, noncoding 
RNA, or protein encoding by the gene, or it noticeably 
influences signaling of synthesized protein)
•	 It is associated with the risk of cancer in conducted 
studies
•	 It has any functional consequences on the molecular level 
and it is strongly (threshold odds ratio value may be indi-
vidual for each cancer type) associated with conditions 
that significantly increase the risk of cancer.
A gene polymorphism can be also included into the 
extended list if:
•	 It is characterized by more subtle functional alterations 
in the gene that, however, still result in qualitative or 
  quantitative alterations of the encoding protein (or 
  noncoding RNA)
•	 It is associated only with conditions that substantially 
increase the risk of cancer (ie, not associated with the 
risk of cancer).
In concordance with this conception, the following SNPs 
of genes encoding PRRs and proteins of PRR signaling 
pathways may be accepted as the most valuable for further 
oncogenomic investigations based on the analysis of relevant 
published literature:63–65
•	 TLR1-TLR6-TLR10 gene cluster: rs10008492, rs4833103, 
rs5743815, rs11466657
•	 TLR2 gene: rs3804100, rs4696480, -196 to -174 del 
(Delta22), GT-microsatellite polymorphism
•	 TLR4 gene: rs4986790, rs4986791, rs16906079, 
rs11536891, rs7873784, rs1927911, rs10759932, 
rs10116253, rs11536889, rs11536858
•	 TLR9 gene: rs5743836, rs352140
•	 TIRAP/MAL gene: rs8177400, rs8177399, rs8177374, 
rs7932766
•	 MyD88 gene: rs1319438, rs199396
•	 IRAK1 gene: rs1059703, rs3027898, rs10127175
•	 TRAF3 gene: rs7143468, rs12147254, rs11160707
•	 TRAF6 gene: rs331455, rs331457
•	 TOLLIP gene: rs5743867
•	 IRF3 gene: rs7251
•	 IRF5 gene: rs2004640, rs2280714, rs10954213, 5 bp 
indel (CGGGG) polymorphism
•	 NOD1 gene: rs2075820, ND(1) +	32656
•	 NOD2 gene: rs2066842, rs2066844, rs2066845, 
rs2006847
•	 MRC1 gene: rs1926736, rs2478577, rs2437257, rs691005
•	 CD209 gene: rs2287886, rs735239, rs735240, rs4804803
•	 CLEC7A gene: rs16910526
•	 RIG-I gene: rs36055726, rs11795404, rs10813831.
Although gene polymorphisms of genes encoding RLRs, 
CLRs, and specific proteins of their signaling pathways are 
investigated relatively less than SNPs of TLRs and NOD-like 
receptors, it is possible to conclude that since they recognize 
bacterial, viral, fungal, protozoan, and helminth pathogen-
associated molecular patterns as TLRs and NOD-like recep-
tors, inherited structural variation in them may influence 
cancer risk and progression as well. For instance, some 
human CLRs (MRC1, CD207, LY75, CD209, CLEC7A, 
CLEC1B, CLEC6A, CLEC4E, CLEC4A) recognize ligands3 
of potentially carcinogenic infectious agents,12,13 such as 
M. tuberculosis,66 S. pneumoniae,67 Klebsiella pneumoniae,68 
human immunodeficiency virus-1,69 cytomegalovirus,70 
Candida albicans,71 C. neoformans,72 Pneumocystis carinii,73 
Paracoccidioides brasiliensis,74   Histoplasma capsulatum,74 
and Schistosoma mansoni.75 Many polymorphisms of genes 
encoding these receptors may alter immune response to 
indicated ligands, possibly, modulating etiopathogenesis of 
certain cancer types such as lung cancer (M. tuberculosis, 
S. pneumoniae, and K. pneumoniae),12,13 glioblastoma 
(cytomegalovirus),76 oral cancer (fungi),77 colorectal cancer, 
hepatocellular carcinoma, prostate cancer, or cervical cancer 
(S. mansoni).78 One RLR, RIG-I, also recognizes ligands 
of hepatitis C virus and EBV ,4 and thus structural inherited 
variation in this receptor may alter risk of hepatocellular 
carcinoma, nasopharyngeal carcinoma, and lymphoma.
There are certain disparities in different population stud-
ies investigating the association of polymorphisms of genes 
encoding PRRs and proteins of their signaling pathways 
with various aspects of cancer development.63–65 General 
reasons for these discrepancies may include confounding 
host, bacterial, or environmental factors in different ethnici-
ties modulating penetrance of variant allele and affecting 
risk of conditions increasing cancer risk (such as autoim-
mune diseases, precancerous gastric lesions, tuberculosis, 
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and recurrent pneumonia), different bacterial impact in 
  etiology of such conditions in   different populations (that 
will be reflected in different   features of PRR-mediated 
immune response because of specific   PRR-ligand interac-
tion),   differences in sample size, differences in age/gender/
body mass index/ethnicity/tumor, node, metastasis stage/
other clinicopathological characteristics between study 
samples, differences in prevalence of infectious agent (eg, 
Helicobacter pylori or EBV) in case and control groups, 
and differences in diagnostics, stratification, genotyping 
  methods, and chance. In addition, certain studies in which 
negative results were obtained could never have been pub-
lished (so-called “file drawer effect”), which may create a 
significant bias and distort a picture that cannot be observed 
at the moment. Unfortunately, although some genome-wide 
association studies relevant to the discussed problem were 
performed, it is usually not possible to compare them with 
non-genome-wide association studies on the same cancer 
type since there are no non-genome-wide association studies 
investigating association of the same SNPs with similar 
malignancies. It may be feasible in the future when the 
number of studies devoted to this issue will be enough for 
correct comparative analysis.
Future directions
The most intriguing aspects of the problem of the association 
of inherited structural variation in genes encoding PRRs and 
proteins of PRR signaling pathways with features of cancer 
development are:
•	 Are SNPs in genes encoding PRRs or proteins of PRR 
signaling pathways associated with features of cancer 
progression or only with cancer risk? Existing studies 
show controversial results, and most of  the results suggest 
that there is no, or weak, correlation between such poly-
morphisms and peculiarities of cancer progression.
•	 Are polymorphisms of genes encoding CLRs, RLRs, or 
specific proteins of their signaling pathways connected 
with risk or progression of cancer? If yes, would it be 
appropriate to include them in the list of polymorphisms 
used in programs of cancer risk determination and   further 
cancer prevention? As shown above, there is some   premise 
to the thought that these SNPs may be associated with 
cancer risk. Further fundamental and population studies 
are necessary to answer to this question.
•	 Do polymorphisms of genes encoding PRRs or proteins 
of PRR signaling pathways (particularly TLRs and 
TLR pathway) correlate with altered prostate cancer 
risk or progression? Almost all large studies devoted to 
this issue showed that there is no association between 
  inherited variation in indicated genes and features of 
prostate cancer development.
•	 Are polymorphisms of genes of PRR signaling pathways 
associated with cancer risk or progression to the same 
extent as polymorphisms of genes encoding PRRs? It 
is logical that if SNP of gene encoding specific PRR 
is associated with risk or progression features of cer-
tain malignancies, polymorphisms in genes encoding 
specific signaling molecules constituting pathways of 
these receptors should correlate with similar neoplasms, 
if they have substantial functional consequences on the 
molecular level.
•	 How do polymorphisms of genes encoding PRRs and 
proteins of PRR signaling pathways interact with each 
other in relation to determination of cancer risk and 
progression? Particularly, how do SNPs of positive and 
negative regulators of PRR activity (especially, micro 
RNA) influence cancer risk or progression if they are 
inherited together? Answers to these questions remain 
elusive at the present time and should be obtained from 
fundamental and population studies in the future.
•	 Which SNPs of genes encoding PRRs and proteins of 
PRR pathways have independent significance, and which 
are just in the linkage disequilibrium? Knowledge of this 
may help in creating the list of polymorphisms useful 
in programs of cancer risk determination and further 
prevention.
•	 Which SNPs of genes encoding PRRs and proteins 
of PRR pathways should be included in such a list? 
Which of them have universal effect for each cancer 
type, and which influence risk and progression of one 
cancer type but have no effect in relation to another 
malignancy? Differences in association of the same 
SNP with different malignancies should be explained 
by features of specific pathogen-associated molecular 
pattern–PRR interaction (probably certain characteris-
tics of ligand binding), or, possibly, on peculiarities of 
damage-associated molecular pattern–PRR interaction. 
Lists of prospective SNPs for further oncogenomic 
investigations may be created according to the concept 
suggested above.
•	 How do SNPs of genes encoding PRRs and proteins of 
PRR pathways affect cancer risk or progression in dif-
ferent populations and subgroups of such populations? 
How can this information be adjusted for application in 
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the creation of programs of cancer risk determination 
and further prevention? Only large, comprehensive, 
  well-designed population studies may provide an answer 
to these questions.
•	 Do polymorphisms of genes encoding PRRs and proteins 
of PRR pathways influence cancer risk only through 
increase in risk of chronic inflammatory conditions, or 
can they affect it through other mechanisms as well? How 
can this information be used in programs of cancer risk 
determination and further prevention? To answer these 
questions, control groups in population studies should 
include not only healthy controls, but also controls with 
chronic inflammatory conditions predisposed to investi-
gating cancer type.
•	 Which infectious agents recognized by various PRRs are 
carcinogenic, and which are not? It may help to define 
cancer types associated with SNPs of genes encoding 
specific PRRs and proteins constituting PRR signaling 
pathways. Fundamental studies devoted to the investiga-
tion of infectious agent–PRR interactions, to the investi-
gation of carcinogenicity of known infectious agents and 
to the discovery of new, possibly carcinogenic, infectious 
agents should answer this question.
No doubt, determination of the role of SNPs in genes 
encoding PRRs and proteins of PRR signaling pathways in 
fields of tumor immunology and molecular epidemiology of 
cancer may open new pages in cancer biology and cancer 
prevention.
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